A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients

Takahiko Sasaki, Katsutoshi Nakayama, Hiroyasu Yasuda, Motoki Yoshida, Takaaki Asamura, Takashi Ohrui, Hiroyuki Arai, Jun Araya, Kazuyoshi Kuwano, Mutsuo Yamaya

Research output: Contribution to journalArticlepeer-review

64 Citations (Scopus)

Abstract

OBJECTIVES: To investigate whether proton pump inhibitor (PPI) therapy reduces the frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease (COPD). DESIGN: Twelve-month, randomized, observer-blind, controlled trial. SETTING: A university hospital and three city hospitals in Miyagi prefecture in Japan. PARTICIPANTS: One hundred patients with COPD (mean age ± SD 74.9 ± 8.2) participated. They were all ex-smokers and had received conventional therapies for COPD, including smoking cessation and bronchodilators. Patients with gastroesophageal reflux disease or gastroduodenal ulcer were excluded. INTERVENTION: Patients were randomly assigned to conventional therapies (control group) or conventional therapies plus PPI (lansoprazole 15 mg/d; PPI group) and observed for 12 months. MEASUREMENTS: Frequency of common colds and COPD exacerbations. RESULTS: The number of exacerbations per person in a year in the PPI group was significantly lower than that in the control group (0.34 ± 0.72 vs 1.18 ± 1.40; P<.001). The adjusted odds ratio with logistic regression for having exacerbation (≥once/year) in the PPI group compared with the control group was 0.23 (P=.004). In contrast, there was no significant difference in the numbers of common colds per person per year between the PPI group and the control group (1.22 ± 2.09 vs 2.04 ± 3.07; P=.12). PPI therapy significantly reduced the risk of catching frequent common colds (≥3 times/year), the adjusted odds ratio of which was 0.28 (P=.048). CONCLUSION: In this single-blind, nonplacebo-controlled trial, lansoprazole was associated with a significant decrease in COPD exacerbations. More definitive clinical trials are warranted.

Original languageEnglish
Pages (from-to)1453-1457
Number of pages5
JournalJournal of the American Geriatrics Society
Volume57
Issue number8
DOIs
Publication statusPublished - 2009 Aug

Keywords

  • Chronic obstructive pulmonary disease
  • Common cold
  • Exacerbation
  • Lower airway infection
  • Proton pump inhibitor

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients'. Together they form a unique fingerprint.

Cite this